BCL2 and leukemia: Pharmacological inhibition of FA oxidation decreased the number of quiescent leukemia progenitor cells in approximately 50% of primary human AML samples, sensitized leukemia cells to apoptosis induction by ABT-737 (mediated by proapoptotic Bcl-2 family members) and, when combined with either ABT-737 or cytosine arabinoside, had therapeutic effect in xenografts of AML cell lines in nude mice [140] (Figure 6).